PRESCRIBE 8 WEEKS OF MAVIRET
FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS1
PRESCRIBE 8 WEEKS OF MAVIRET
FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS1
MAVIRET FOR HEPATITIS C
MAVIRET is indicated for the treatment of patients 3 years and older with chronic HCV GT 1-6 infection with or without compensated cirrhosis. This includes patients with HCV GT1 infection who were previously treated with either a regimen of an NS5A inhibitor or with an NS3/4A protease inhibitor but not both classes of inhibitors.1*
*Please refer to the Product Information for further guidance on the appropriate MAVIRET dose depending on the patient's age and weight. MAVIRET granule presentation is not reimbursed in Australia.
THE SHORTEST
ROUTE TO
CURE* HEP C†1-2
with 8-week MAVIRET.1
†For GT1–6 treatment-naïve non-cirrhotic or compensated-cirrhotic patients, 8-week MAVIRET vs. 12-week EPCLUSA.1,2 *Cure defned as sustained virologic response (HCV RNA below the limit of detection) at 12 weeks post end of treatment (SVR12). 98% SVR12 in treatment-naïve non-cirrhotic and compensated cirrhotic patients (n=1218/1248, ITT; pooled analysis).3
In patients at risk of loss to follow-up:
DELIVER THEIR RESULTS EARLIER WITH SVR4.‡1,4,5
‡SVR4 vs SVR12. Australian Hepatitis C Guidelines state that opportunistic testing can be performed at any time from 4 weeks post end-of-treatment (SVR4) for patients at risk of loss to follow-up.4
99.8% concordance of SVR4 with SVR12 in HCV GT1-6 infected adult and adolescent patients (n=2,855) treated with label consistent duration of MAVIRET (PPV=99.8%; NPV=100%; integrated analysis).1
THE SHORTEST
ROUTE TO
CURE* HEP C†1-2
with 8-week MAVIRET.1
†For GT1–6 treatment-naïve non-cirrhotic or compensated-cirrhotic patients, 8-week MAVIRET vs. 12-week EPCLUSA.1,2 *Cure defned as sustained virologic response (HCV RNA below the limit of detection) at 12 weeks post end of treatment (SVR12). 98% SVR12 in treatment-naïve non-cirrhotic and compensated cirrhotic patients (n=1218/1248, ITT; pooled analysis).3
In patients at risk of loss to follow-up:
DELIVER THEIR RESULTS EARLIER WITH SVR4.‡1,4,5
‡SVR4 vs SVR12. Australian Hepatitis C Guidelines state that opportunistic testing can be performed at any time from 4 weeks post end-of-treatment (SVR4) for patients at risk of loss to follow-up.4
99.8% concordance of SVR4 with SVR12 in HCV GT1-6 infected adult and adolescent patients (n=2,855) treated with label consistent duration of MAVIRET (PPV=99.8%; NPV=100%; integrated analysis).1
Patients who are treatment experienced and/or compensated cirrhotic may require longer treatment duration with MAVIRET.
Please refer to Product Information.
MANAGEMENT OF HCV FOR PRESCRIBERS
MANAGEMENT OF HCV FOR CORRECTIONAL FACILITIES
MANAGEMENT OF HCV FOR DRUG AND ALCOHOL TREATMENT SERVICES
MANAGEMENT OF HCV FOR NURSES
PBS Information
Maviret: Authority required. Refer to PBS Schedule for full authority information.
Please review the full Product Information (PI) before prescribing, available below.
REFERENCES: 1. MAVIRET Approved Product Information. 2. EPCLUSA Approved Product Information. 3. Zuckerman E et al. Clin Gastroenterol 2020;18(11):2544-53.e6 4. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (2022). Available at: https://www.hepcguidelines.org.au Accessed January 2024 5. Gane E et al. J Viral Hepat 2021;28:1635–42
ABBREVIATIONS: GT=genotype. HCV=hepatitis C virus. HEP C=hepatitis C. NPV=negative predictive value. pegIFN=peginterferon. PPV=positive predictive value. RBV=ribavirin. RNA=ribonucleic acid. SVR=sustained virologic response.
AU-MAVI-220152. February 2024.